Lecanemab was approved in the U.S. in 2023 as the world's first drug to slow the cognitive decline associated with Alzheimer's. The treatment also has received approval in Japan, China, Europe and ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

Awards Program Recognizes Standout Digital Health & Medical Technology Products and CompaniesLOS ANGELES, May 08, 2025 (GLOBE ...

TOKYO -- Japanese drugmaker Eisai is overhauling its U.S. operations as the company seeks ways to overcome the hurdles to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...